Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus.
Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking at an Irrandiance of 18 mW/cm2 in Eyes With Keratoconus or Ectasia.
  • Phase

    Phase 2
  • Study Type

  • Status

  • Intervention/Treatment

    ribavirin ...
  • Study Participants

This study is being conducted to assess the safety and effectiveness of photochemically induced collagen cross- linking (CCL) at irradiance of 18mW/cm2 in eyes with Keratoconus and Ecstasia.
Riboflavin drops are used every 2 minutes for 30+ minutes until the corneal stroma is saturated with Riboflavin as evidenced by observing Riboflavin in the Anterior chamber. Two arms in the study, one uses Riboflavin with Epithelium on and the other with Epithelium off. Once it is observed that the Riboflavin has penetrated the stroma and is seen in the anterior chamber, the cornea is exposed to Ultraviolet light at an irradiance level of 18mW/cm2 for 5 minutes. A contact lens is applied until the epithelium has fully healed in 3 to 5 days. The study is for 6 months. The corneal curvature as well as the uncorrected and best corrected vision and corneal thickness are evaluated pre-operatively and at 6 months. The primary variable that is assessed to determine the efficacy of the drug is the Kmax - Steep corneal curvature. Secondary effectiveness criteria are uncorrected and best corrected vision and corneal thickness. adverse events are also monitored.
Study Started
Sep 30
Primary Completion
Apr 30
Study Completion
Apr 30
Last Update
May 05

Drug Riboflavin drops

Riboflavin drops were used every 2 minutes for 30 minutes on the cornea then exposed to 5 minutes of Ultraviolet light at an intensity of 18mW/cm2

  • Other names: Rincolin

Riboflavin drops - epithelium on or off Other

Riboflavin is applied with Epithelium on or with it off. 6 months follow up to find out magnitude of Decrease in Kmax



12 years of age or older
Signed written informed consent
Willingness and ability to comply with schedule for follow-up visits
Contact lens removal prior to evaluation and treatment

Candidates must also have two of the following criteria:

Presence of central or inferior steepening on the Pentacam or Orbscan map consistent with Keratoconus.
Axial topography consistent with keratoconus.
Steepest keratometry (Kmax) value of 47.00D


History of having undergone a keratorefractive procedure and 2 of the following criteria:

Steepening by topography, either Pentacam or Orbscan
Thinning of cornea
Shift in the position of thinnest portion of cornea
Change in refraction with increasing myopia
Development of myopic astigmatism
Development of irregular astigmatism

Loss of BSCVA


I. Eyes classified as either normal or atypical normal 2. Corneal pachymetry 350 microns at the thinnest point measured by Pentacam in the eye to be treated 3. A history of chemical injury or delayed epithelial healing in the eye to be treated.

4. Pregnancy (including plan to become pregnant) or lactation during the course of the study 5. A known sensitivity to study medications 6. Patients with nystagmus or any other condition that would prevent a steady gaze during the treatment 7. Inability to cooperate with diagnostic tests. 8. Patients with a concomitant condition that, in the investigator's opinion, would interfere with or prolong epithelial healing.

9. Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking treatment.

10. Patients who are unable to remain supine and tolerate a lid speculum for an extended period of time.

No Results Posted